PH94B Nasal Spray for Social Anxiety Disorder

(Palisade-2 Trial)

No longer recruiting at 15 trial locations
CB
PP
Overseen ByPayal Patel, PharmD
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: VistaGen Therapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a nasal spray called PH94B to determine its effectiveness in reducing anxiety for people with social anxiety disorder (SAD) during public speaking. Participants will use the nasal spray before facing a public speaking challenge to assess the spray's effectiveness. The trial seeks adults diagnosed with social anxiety disorder who frequently experience anxiety when speaking in front of others. As a Phase 3 trial, this study serves as the final step before potential FDA approval, providing participants an opportunity to contribute to the development of a new treatment for social anxiety disorder.

Do I need to stop taking my current medications to join the trial?

Yes, you will need to stop taking any psychotropic medications, anxiolytics (medications for anxiety), and any over-the-counter or herbal products for anxiety 30 days before joining the study and during the study.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that the PH94B nasal spray is generally safe. In earlier studies, only about 2.9% of participants stopped using the spray due to side effects like a stuffy nose or discomfort. Most other side effects were mild or moderate, such as slight irritation. Overall, most people can use the spray without problems. This information supports the safety of PH94B for treating anxiety.12345

Why do researchers think this study treatment might be promising for social anxiety disorder?

Unlike the standard treatments for anxiety, which often include oral medications like SSRIs and benzodiazepines, PH94B nasal spray offers a novel approach by acting directly through the nasal passages. This unique delivery method allows PH94B to potentially provide rapid relief from anxiety during public speaking, targeting the nasal chemosensory receptors to quickly influence brain regions involved in emotional processing. Researchers are excited because this intranasal spray could offer fast-acting anxiety relief without the systemic effects typically associated with oral medications, making it a promising option for situational anxiety.

What evidence suggests that this trial's treatments could be effective for social anxiety disorder?

Research has shown that PH94B nasal spray, which participants in this trial may receive, might help reduce anxiety symptoms related to social anxiety disorder (SAD). In a recent study, Vistagen found that the nasal spray successfully reduced anxiety during social situations. Early results suggest that the spray works quickly to calm nerves by reducing the body's stress response. This treatment is generally well-tolerated, with most people experiencing no serious side effects. Overall, PH94B appears to be a promising option for quick relief in anxiety-inducing situations like public speaking.678910

Who Is on the Research Team?

ML

Michael Liebowitz

Principal Investigator

Medical Research Network

Are You a Good Fit for This Trial?

Inclusion Criteria

SAD is currently diagnosed by checking for symptoms in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and confirming those symptoms with the MINI.
The clinician rated the individual's LSAS total score as ≥70 at Screening.
The Hamilton Depression Score was less than eighteen at the screening visit.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

3 to 35 days
1 visit (in-person)

Treatment

Participants self-administer the nasal spray and participate in a 5-minute public speaking challenge

1 day
2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including repeat safety and psychiatric assessments

1 week
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • PH94B Nasal Spray
  • Placebo Nasal Spray
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment1 Intervention
Group II: PH94BExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

VistaGen Therapeutics, Inc.

Lead Sponsor

Trials
12
Recruited
1,900+

Citations

NCT02622958 | Feasibility Study of PH94B Nasal Spray for ...The purpose of the study is to determine whether the PH94B nasal spray is effective for Acute Treatment of the symptoms of Social Anxiety Disorder (SAD) in ...
Vistagen's Innovative Treatment for Social AnxietyIn the second half of 2023, Vistagen reported positive results from its PALISADE-2 Phase 3 trial of fasedienol in adults with SAD, with the trial meeting its ...
3.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/24700254/
Effect of an acute intranasal aerosol dose of PH94B on ...Conclusions: PH94B may be a novel, effective, and well-tolerated acute treatment for performance and social anxiety in women with social anxiety disorder. Trial ...
NCT05011396 | PH94B Nasal Spray for Anxiety Induced ...This Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute administration of 3.2 µg of PH94B to relieve ...
Effect of fasedienol (PH94B) pherine nasal spray and ...Results suggest that rapid onset of effects from fasedienol counteract heightened sympathetic activation and reduce symptoms of anxiety ...
Vistagen Presents Fasedienol (PH94B) Safety and ...“These data advance the body of evidence supporting fasedienol's safety profile and potential to achieve overall reduction in anxiety for adults.
A Phase 3 Open-label Safety Trial of Fasedienol (PH94B) ...TEAE, treatment-emergent adverse event. • Fourteen patients (2.9%) experienced a TEAE leading to discontinuation. ─ Nasal congestion, rhinalgia, ...
PH94B in the Treatment of Adjustment Disorder With AnxietyThis placebo-controlled clinical study is designed to evaluate the efficacy, safety and tolerability of administration of PH94B nasal spray four times per ...
Intranasal Fasedienol Appears to Be Safe, Effective for ...An evaluation of safety and tolerability showed that 54.9% of patients reported mild or moderate treatment emergent adverse events, with ...
Study Details | NCT06809179 | A Clinical Trial to Assess ...A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security